ABBOTT LABORATORIES Effective Income Tax Rate Reconciliation Fdii Percent
ABBOTT LABORATORIES (ABT) reported Effective Income Tax Rate Reconciliation Fdii Percent of 1.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent · last filed 2026-02-20
- ABBOTT LABORATORIES effective income tax rate reconciliation fdii percent for fiscal 2025 was 1.70%, a 26.09% decline from fiscal 2024.
- ABBOTT LABORATORIES effective income tax rate reconciliation fdii percent for fiscal 2024 was 2.30%, a 4.55% increase from fiscal 2023.
- ABBOTT LABORATORIES effective income tax rate reconciliation fdii percent for fiscal 2023 was 2.20%, a 10.00% increase from fiscal 2022.
- ABBOTT LABORATORIES effective income tax rate reconciliation fdii percent for fiscal 2022 was 2.00%, a 81.82% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation Fdii Percent 12 month |
|---|---|
| 2025-12-31 | 1.70% 10-K · filed 2026-02-20 |
| 2024-12-31 | 2.30% 10-K · filed 2026-02-20 |
| 2023-12-31 | 2.20% 10-K · filed 2026-02-20 |
| 2022-12-31 | 2.00% 10-K · filed 2025-02-21 |
| 2021-12-31 | 1.10% 10-K · filed 2024-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |